NASDAQ:CELU Celularity (CELU) Stock Price, News & Analysis $1.44 +0.06 (+4.35%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Celularity Stock (NASDAQ:CELU) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Celularity alerts:Sign Up Key Stats Today's Range$1.36▼$1.5850-Day Range$1.38▼$3.0852-Week Range$1.30▼$7.97Volume38,219 shsAverage Volume98,293 shsMarket Capitalization$31.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCelularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Read More… 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Celularity Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks1st Percentile Overall ScoreCELU MarketRank™: Celularity scored higher than 1% of companies evaluated by MarketBeat, and ranked 975th out of 976 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Celularity.Read more about Celularity's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioCelularity has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Celularity's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.35% of the float of Celularity has been sold short.Short Interest Ratio / Days to CoverCelularity has a short interest ratio ("days to cover") of 40.3, which indicates bearish sentiment.Change versus previous monthShort interest in Celularity has recently increased by 0.19%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCelularity does not currently pay a dividend.Dividend GrowthCelularity does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.35% of the float of Celularity has been sold short.Short Interest Ratio / Days to CoverCelularity has a short interest ratio ("days to cover") of 40.3, which indicates bearish sentiment.Change versus previous monthShort interest in Celularity has recently increased by 0.19%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows2 people have added Celularity to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Celularity insiders have not sold or bought any company stock.Percentage Held by Insiders20.70% of the stock of Celularity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.02% of the stock of Celularity is held by institutions.Read more about Celularity's insider trading history. Receive CELU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Celularity and its competitors with MarketBeat's FREE daily newsletter. Email Address CELU Stock News HeadlinesCelularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings PanelOctober 23, 2024 | globenewswire.comCelularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an AppealOctober 18, 2024 | globenewswire.comCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!November 2, 2024 | Crypto 101 Media (Ad)Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.October 16, 2024 | globenewswire.comCelularity anuncia la salida de un ejecutivoSeptember 15, 2024 | es.investing.comCelularity to Present at H.C. Wainwright’s 26th Annual Global Investment ConferenceSeptember 5, 2024 | markets.businessinsider.comCelularity to Present at H.C. Wainwright's 26th Annual Global Investment ConferenceSeptember 5, 2024 | globenewswire.comUnlocking the Secrets of Immortality: KCSA Podcast Labs Dives into $43 Billion Longevity IndustrySeptember 4, 2024 | markets.businessinsider.comSee More Headlines CELU Stock Analysis - Frequently Asked Questions How have CELU shares performed this year? Celularity's stock was trading at $2.4740 on January 1st, 2024. Since then, CELU stock has decreased by 41.8% and is now trading at $1.44. View the best growth stocks for 2024 here. How were Celularity's earnings last quarter? Celularity Inc. (NASDAQ:CELU) announced its earnings results on Wednesday, October, 16th. The company reported ($1.03) earnings per share (EPS) for the quarter. The business had revenue of $14.68 million for the quarter. Celularity had a negative net margin of 460.34% and a positive trailing twelve-month return on equity of 65.58%. When did Celularity's stock split? Shares of Celularity reverse split on the morning of Thursday, February 29th 2024. The 1-10 reverse split was announced on Thursday, February 29th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Celularity? Shares of CELU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Celularity own? Based on aggregate information from My MarketBeat watchlists, some other companies that Celularity investors own include NVIDIA (NVDA), Meta Platforms (META), Lovesac (LOVE), MannKind (MNKD), PayPal (PYPL), Tesla (TSLA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings10/16/2024Today11/01/2024Fiscal Year End12/31/2024Next Earnings (Estimated)1/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CELU CUSIPN/A CIK1752828 Webwww.celularity.com Phone908-768-2170FaxN/AEmployees220Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-196,290,000.00 Net Margins-460.34% Pretax Margin-460.31% Return on Equity65.58% Return on Assets20.96% Debt Debt-to-Equity RatioN/A Current Ratio0.35 Quick Ratio0.29 Sales & Book Value Annual Sales$22.77 million Price / Sales1.39 Cash Flow$6.86 per share Price / Cash Flow0.21 Book Value$2.11 per share Price / Book0.68Miscellaneous Outstanding Shares21,990,000Free Float17,434,000Market Cap$31.67 million OptionableOptionable Beta0.44 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report This page (NASDAQ:CELU) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celularity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.